Thrive Capital Management (Pennsylvania)’s AstraZeneca AZN Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$441K	Buy	+2,235	New	+$431K	0.1%	130

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Thrive Capital Management (Pennsylvania)'s AZN Position: Q1 2026 in Review

Thrive Capital Management (Pennsylvania) opened a new position in AstraZeneca (AZN) in Q1 2026: 2,235 shares worth $441K. The stake represents 0.1% of the portfolio and ranks #130 among its holdings.

1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Thrive Capital Management (Pennsylvania) held 2,235 shares of AstraZeneca worth $441K as of Q1 2026.
AstraZeneca was a new Thrive Capital Management (Pennsylvania) position in Q1 2026.
AstraZeneca made up 0.1% of Thrive Capital Management (Pennsylvania)'s portfolio in Q1 2026, its #130 holding.
1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q1 2026, filed 27 Apr 2026.